Cardiff Oncology (CRDF) Expected to Beat Earnings Estimates: Should You Buy?
Cardiff Oncology (CRDF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
All You Need to Know About Cardiff Oncology (CRDF) Rating Upgrade to Buy
Cardiff Oncology (CRDF) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cardiff Oncology, Inc. (CRDF) Q4 2024 Earnings Call Transcript
Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q4 2024 Earnings Conference Call February 27, 2025 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Jamie Levine - Chief Financial Officer Conference Call Participants Joe Catanzaro - Piper Sandler Andy Hsieh - William Blair Robert Burns - H.C. Wainwright Albert Lowe - Craig-Hallum Operator Welcome to the Cardiff Oncology Fourth Quarter 2024 Financial Results and Business Update Conference Call.
Cardiff Oncology (CRDF) Reports Q4 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.21 per share a year ago.
Cardiff Oncology: Pioneering RAS-Mutated Cancer Therapies With Onvansertib
Cardiff Oncology's Onvansertib shows promise in treating RAS-mutated cancers, especially mCRC, with a strong therapeutic profile and potential for high returns if approved. Onvansertib's Phase II results indicate superior efficacy in first-line treatment, supporting Cardiff's financial stability and long-term investment potential. The competitive landscape includes therapies like LUMAKRAS and KRAZATI, but Onvansertib's mutation-agnostic approach offers a unique advantage.
Cardiff Oncology: The Long-Awaited First-Line MCRC Data Are Here, But The Work Is Just Beginning
Cardiff Oncology's phase 2 trial of onvansertib in mCRC shows promising preliminary data, with improved response rates in a dose-dependent manner. Onvansertib appears well tolerated and effective when combined with standard chemotherapy and bevacizumab, but patient numbers remain low, necessitating further validation. Financially, CRDF's equity raise extends their cash runway, supporting the continued development and reducing immediate financial risk.
CRDF Stock Soars on Robust Efficacy Data From Colorectal Cancer Study
Cardiff Oncology stock rallies as initial data from a phase II study of onvansertib shows superior efficacy over SOC chemotherapy in colorectal cancer patients.
Cardiff Oncology: Beats Standard Of Care In First Line Metastatic Colorectal Cancer
Cardiff Oncology's Phase 2 trial data for Onvansertib in metastatic colorectal cancer shows dose-related outperformance of standard care, with a combined ORR of 57% versus 33% in the control arm. The company plans to discuss with the FDA to potentially make the CRDF-004 trial a registrational trial, aiming for accelerated approval based on ORR. Cardiff's recent $40 million oversubscribed direct offering strengthens its financial position, ensuring over two years of operational funding.
Cardiff Oncology (CRDF) Reports Q3 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.25 per share versus the Zacks Consensus Estimate of a loss of $0.27. This compares to loss of $0.22 per share a year ago.
Cardiff: Second Half Of 2024 mCRC Data Is Major Inflection Point
Cardiff Oncology, Inc. results from the phase 2 CRDF-004 study, using onvansertib + Folfiri + bevacizumab for the treatment of patients with RAS-mutant mCRC, expected in the 2nd half of 2024. The global colorectal cancer market is expected to reach $30.09 billion by 2033; It said that about 50% of mCRC patients harbor the RAS mutation. A new phase 2 investigator-sponsored study, using onvansertib + Nalirifox for the treatment of 1st-line PDAC patients, will be deployed soon.
Cardiff Oncology, Inc. (CRDF) Q2 2024 Earnings Call Transcript
Cardiff Oncology, Inc. (NASDAQ:CRDF ) Q2 2024 Results Conference Call August 8, 2024 4:30 PM ET Company Participants Kiki Patel - Investor Relations, Gilmartin Group Mark Erlander - Chief Executive Officer Jamie Levine - Chief Financial Officer Conference Call Participants Andy Hsieh - William Blair Marc Frahm - TD Cowen Operator Welcome to the Cardiff Oncology Second Quarter 2024 Financial Results and Business Update Conference Call. [Operator Instructions] Please be advised that today's conference is being recorded.
Cardiff Oncology (CRDF) Reports Q2 Loss, Tops Revenue Estimates
Cardiff Oncology (CRDF) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.25. This compares to loss of $0.25 per share a year ago.
